CEO SUMMARY: At least ten companies are working on an HPV vaccine that can prevent cervical cancer. The leading two companies have Phase III clinical trials under way and expect to earn regulatory approval within the next 24 to 30 months. The speedy arrival of an HPV vaccine in the market will not affect Pap […]
HPV Vaccine Developers Racing to Marketplace
Merck and GlaxoSmithKline both hope to be first to win approval from regulators
- By Robert Michel
- > From the Volume XI No. 16 - November 22, 2004 Issue
